Clinical Trial Update: Pyrotinib Versus Pertuzumab in Combination With Neoadjuvant Trastuzumab and Nab-Paclitaxel in HER2+ Early or Locally Advanced Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial comparing pyrotinib to pertuzumab, in combination with neoadjuvant trastuzumab and nab-paclitaxel, for HER2-positive early or locally advanced bre…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Nab-paclitaxel (paclitaxel protein-bound)
• Pertuzumab (pertuzumab)
• Pyrotinib (pyrotinib)
• Trastuzumab (trastuzumab)

Snippet

Sponsor: Tianjin Medical University Cancer Institute and Hospital | Conditions: HER2+ Early or Locally Advanced Breast Cancer | Phase 2 | Status: UNKNOWN